The following represents disclosure information provided by authors of this abstract. The Genitourinary Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Cost-effectiveness of denosumab (Dmab) versus zoledronic acid (ZA) for prevention of skeletal-related events (SREs) in patients (pts) with castrate-resistant prostate cancer (CRPC) and bone metastases (BM).
Michael E. Rader
Consultant or Advisory Role - Amgen
Honoraria - Amgen
Mark Danese
Consultant or Advisory Role - Amgen
Research Funding - Amgen
Ze Cong
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Marc Halperin
Consultant or Advisory Role - Amgen
Research Funding - Amgen
Yi Qian
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Carsten Dietrich Goessl
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Karen Chung
Employment or Leadership Position - Amgen
Stock Ownership - Amgen